Pembrolizumab and the significance of PD-L1 for lung cancer

Roy Herbst, MD, PhD of Yale School of Medicine, New Haven, CT talks about pembrolizumab and the importance of the PD-L1 biomarker. Prof. Herbst explains that the biomarker does help discriminate patients who will benefit most from the drug. He further explains that patients should now be tested for PD-L1 at diagnosis and those who are PD-L1 positive will receive pembrolizumab and those who are PD-L1 negative will receive other treatment. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
Share this video